vs
吉利德科学（GILD）与Waste Management（WM）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是Waste Management的1.3倍（$7.9B vs $6.2B），吉利德科学净利率更高（27.5% vs 11.6%，领先15.9%），吉利德科学同比增速更快（4.7% vs 3.5%），吉利德科学自由现金流更多（$3.1B vs $981.0M），过去两年吉利德科学的营收复合增速更高（8.9% vs 7.4%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
Waste Management是专业的废弃物管理服务提供商，业务覆盖废弃物从产生到最终处置的全流程，包含垃圾收集、运输、处理、处置等核心环节，同时涉及废弃物管理流程监督、相关法规合规、技术应用及商业机制优化等相关业务。
GILD vs WM — 直观对比
营收规模更大
GILD
是对方的1.3倍
$6.2B
营收增速更快
GILD
高出1.2%
3.5%
净利率更高
GILD
高出15.9%
11.6%
自由现金流更多
GILD
多$2.1B
$981.0M
两年增速更快
GILD
近两年复合增速
7.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $6.2B |
| 净利润 | $2.2B | $723.0M |
| 毛利率 | 79.5% | — |
| 营业利润率 | 25.0% | 17.9% |
| 净利率 | 27.5% | 11.6% |
| 营收同比 | 4.7% | 3.5% |
| 净利润同比 | 22.4% | 13.5% |
| 每股收益（稀释后） | $1.75 | $1.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDWM
| Q1 26 | — | $6.2B | ||
| Q4 25 | $7.9B | $6.3B | ||
| Q3 25 | $7.8B | $6.4B | ||
| Q2 25 | $7.1B | $6.4B | ||
| Q1 25 | $6.7B | $6.0B | ||
| Q4 24 | $7.6B | $5.9B | ||
| Q3 24 | $7.5B | $5.6B | ||
| Q2 24 | $7.0B | $5.4B |
净利润GILDWM
| Q1 26 | — | $723.0M | ||
| Q4 25 | $2.2B | $742.0M | ||
| Q3 25 | $3.1B | $603.0M | ||
| Q2 25 | $2.0B | $726.0M | ||
| Q1 25 | $1.3B | $637.0M | ||
| Q4 24 | $1.8B | $598.0M | ||
| Q3 24 | $1.3B | $760.0M | ||
| Q2 24 | $1.6B | $680.0M |
毛利率GILDWM
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 41.5% | ||
| Q3 25 | 79.8% | 40.5% | ||
| Q2 25 | 78.8% | 40.3% | ||
| Q1 25 | 76.9% | 39.4% | ||
| Q4 24 | 79.1% | 39.7% | ||
| Q3 24 | 79.1% | 39.4% | ||
| Q2 24 | 77.8% | 39.1% |
营业利润率GILDWM
| Q1 26 | — | 17.9% | ||
| Q4 25 | 25.0% | 18.3% | ||
| Q3 25 | 42.8% | 15.3% | ||
| Q2 25 | 34.9% | 17.9% | ||
| Q1 25 | 33.6% | 16.8% | ||
| Q4 24 | 32.4% | 15.6% | ||
| Q3 24 | 11.8% | 20.0% | ||
| Q2 24 | 38.0% | 18.7% |
净利率GILDWM
| Q1 26 | — | 11.6% | ||
| Q4 25 | 27.5% | 11.8% | ||
| Q3 25 | 39.3% | 9.4% | ||
| Q2 25 | 27.7% | 11.3% | ||
| Q1 25 | 19.7% | 10.6% | ||
| Q4 24 | 23.6% | 10.1% | ||
| Q3 24 | 16.6% | 13.5% | ||
| Q2 24 | 23.2% | 12.6% |
每股收益（稀释后）GILDWM
| Q1 26 | — | $1.79 | ||
| Q4 25 | $1.75 | $1.83 | ||
| Q3 25 | $2.43 | $1.49 | ||
| Q2 25 | $1.56 | $1.80 | ||
| Q1 25 | $1.04 | $1.58 | ||
| Q4 24 | $1.43 | $1.49 | ||
| Q3 24 | $1.00 | $1.88 | ||
| Q2 24 | $1.29 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $158.0M |
| 总债务越低越好 | $24.9B | $22.9B |
| 股东权益账面价值 | $22.7B | $10.0B |
| 总资产 | $59.0B | $45.7B |
| 负债/权益比越低杠杆越低 | 1.10× | 2.28× |
8季度趋势，按日历期对齐
现金及短期投资GILDWM
| Q1 26 | — | $158.0M | ||
| Q4 25 | $68.0M | $201.0M | ||
| Q3 25 | $19.0M | $175.0M | ||
| Q2 25 | $69.0M | $440.0M | ||
| Q1 25 | — | $216.0M | ||
| Q4 24 | — | $414.0M | ||
| Q3 24 | — | $614.0M | ||
| Q2 24 | — | $172.0M |
总债务GILDWM
| Q1 26 | — | $22.9B | ||
| Q4 25 | $24.9B | $22.2B | ||
| Q3 25 | $24.9B | $22.5B | ||
| Q2 25 | $24.9B | $23.1B | ||
| Q1 25 | $25.0B | $22.9B | ||
| Q4 24 | $26.7B | $22.5B | ||
| Q3 24 | $23.2B | $16.0B | ||
| Q2 24 | $23.3B | $16.5B |
股东权益GILDWM
| Q1 26 | — | $10.0B | ||
| Q4 25 | $22.7B | $10.0B | ||
| Q3 25 | $21.5B | $9.5B | ||
| Q2 25 | $19.7B | $9.2B | ||
| Q1 25 | $19.2B | $8.7B | ||
| Q4 24 | $19.3B | $8.3B | ||
| Q3 24 | $18.5B | $8.0B | ||
| Q2 24 | $18.3B | $7.5B |
总资产GILDWM
| Q1 26 | — | $45.7B | ||
| Q4 25 | $59.0B | $45.8B | ||
| Q3 25 | $58.5B | $45.6B | ||
| Q2 25 | $55.7B | $45.7B | ||
| Q1 25 | $56.4B | $44.5B | ||
| Q4 24 | $59.0B | $44.6B | ||
| Q3 24 | $54.5B | $34.7B | ||
| Q2 24 | $53.6B | $34.0B |
负债/权益比GILDWM
| Q1 26 | — | 2.28× | ||
| Q4 25 | 1.10× | 2.22× | ||
| Q3 25 | 1.16× | 2.36× | ||
| Q2 25 | 1.27× | 2.51× | ||
| Q1 25 | 1.30× | 2.65× | ||
| Q4 24 | 1.38× | 2.73× | ||
| Q3 24 | 1.26× | 2.00× | ||
| Q2 24 | 1.28× | 2.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $1.5B |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $981.0M |
| 自由现金流率自由现金流/营收 | 39.4% | 15.8% |
| 资本支出强度资本支出/营收 | 2.6% | — |
| 现金转化率经营现金流/净利润 | 1.52× | 2.08× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $3.4B |
8季度趋势，按日历期对齐
经营现金流GILDWM
| Q1 26 | — | $1.5B | ||
| Q4 25 | $3.3B | $1.7B | ||
| Q3 25 | $4.1B | $1.6B | ||
| Q2 25 | $827.0M | $1.5B | ||
| Q1 25 | $1.8B | $1.2B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $4.3B | $1.4B | ||
| Q2 24 | $1.3B | $1.2B |
自由现金流GILDWM
| Q1 26 | — | $981.0M | ||
| Q4 25 | $3.1B | $810.0M | ||
| Q3 25 | $4.0B | $816.0M | ||
| Q2 25 | $720.0M | $813.0M | ||
| Q1 25 | $1.7B | $377.0M | ||
| Q4 24 | $2.8B | $396.0M | ||
| Q3 24 | $4.2B | $577.0M | ||
| Q2 24 | $1.2B | $487.0M |
自由现金流率GILDWM
| Q1 26 | — | 15.8% | ||
| Q4 25 | 39.4% | 12.8% | ||
| Q3 25 | 51.0% | 12.7% | ||
| Q2 25 | 10.2% | 12.6% | ||
| Q1 25 | 24.8% | 6.3% | ||
| Q4 24 | 37.4% | 6.7% | ||
| Q3 24 | 55.2% | 10.3% | ||
| Q2 24 | 17.2% | 9.0% |
资本支出强度GILDWM
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 14.1% | ||
| Q3 25 | 1.9% | 12.0% | ||
| Q2 25 | 1.5% | 11.4% | ||
| Q1 25 | 1.6% | 13.8% | ||
| Q4 24 | 1.9% | 18.9% | ||
| Q3 24 | 1.9% | 13.9% | ||
| Q2 24 | 1.9% | 12.3% |
现金转化率GILDWM
| Q1 26 | — | 2.08× | ||
| Q4 25 | 1.52× | 2.29× | ||
| Q3 25 | 1.35× | 2.64× | ||
| Q2 25 | 0.42× | 2.13× | ||
| Q1 25 | 1.34× | 1.90× | ||
| Q4 24 | 1.67× | 2.53× | ||
| Q3 24 | 3.44× | 1.79× | ||
| Q2 24 | 0.82× | 1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
WM
暂无分部数据
